Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03865212
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:33.250169+00:00
Published At
2026-01-28T00:00:00+00:00
Record Updated At
2026-01-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Choroid Melanoma", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Uveal Melanoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Unresectable Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-28"
protocolSection.identificationModule.nctId
"NCT03865212"
protocolSection.identificationModule.officialTitle
"Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Clinical Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Metastatic Choroid Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Mucosal Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Uveal Melanoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Unresectable Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.